DE SCR157

Designates May 5-11, 2024, as "Tardive Dyskinesia Awareness Week" in Delaware.

Recognizes that tardive dyskinesia (TD) is an involuntary movement disorder characterized by uncontrollable, abnormal, and repetitive movements that can result from prolonged use of dopamine receptor blocking medications used to treat serious mental illnesses and gastrointestinal disorders.

Notes that approximately 600,000 people in the United States have TD, with about 65 percent remaining undiagnosed, highlighting the need for increased awareness and screening.

Encourages Delawareans experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare providers and become better informed about tardive dyskinesia.

Acknowledges that FDA-approved treatments for TD exist and that the Department of Health and Social Services can help raise awareness among the public and medical community.